Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Xynomic Pharmaceuticals Holdings stock

XYNO
US98421X1028

Price

2.22
Today +/-
+0
Today %
+0 %
P

Xynomic Pharmaceuticals Holdings stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Xynomic Pharmaceuticals Holdings stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Xynomic Pharmaceuticals Holdings stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Xynomic Pharmaceuticals Holdings stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Xynomic Pharmaceuticals Holdings's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Xynomic Pharmaceuticals Holdings Stock Price History

DateXynomic Pharmaceuticals Holdings Price
5/12/20212.22 undefined
4/28/20212.16 undefined

Xynomic Pharmaceuticals Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Xynomic Pharmaceuticals Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Xynomic Pharmaceuticals Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Xynomic Pharmaceuticals Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Xynomic Pharmaceuticals Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Xynomic Pharmaceuticals Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Xynomic Pharmaceuticals Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Xynomic Pharmaceuticals Holdings’s growth potential.

Xynomic Pharmaceuticals Holdings Revenue, EBIT and net profit per share

DateXynomic Pharmaceuticals Holdings RevenueXynomic Pharmaceuticals Holdings EBITXynomic Pharmaceuticals Holdings Net Income
20190 undefined-25.04 M undefined-25.1 M undefined
20180 undefined-835,930 undefined266,630 undefined
20170 undefined-365,220 undefined-41,260 undefined
20160 undefined-1,800 undefined-1,800 undefined

Xynomic Pharmaceuticals Holdings Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2016201720182019
0000
----
----
0000
000-25
----
000-25
----
6.631.872.4332.28
----
Details

Keystats

ⓘ

Revenue and Growth

The Xynomic Pharmaceuticals Holdings Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Xynomic Pharmaceuticals Holdings is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (k)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (k)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (k)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (k)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2016201720182019
       
300210.09122.6292.66
0000
0000
0000
3089.5327.3330.07
330299.62149.92422.73
000290.42
062.2163.310.01
0000
0001.06
0000
23000214.26
0.2362.2163.310.51
0.5662.5163.460.94
       
0.035.0462.470
00036.82
0-43.06223.57-59,427
00038.82
0000
0.03562.69-22.56
140000
00020.8
0.09002.21
3000600483.85
0000
0.5300.623.5
0000
0000
0000
0000
0.5300.623.5
0.56563.30.94
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Xynomic Pharmaceuticals Holdings provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Xynomic Pharmaceuticals Holdings's financial health and stability.

Assets

Xynomic Pharmaceuticals Holdings's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Xynomic Pharmaceuticals Holdings must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Xynomic Pharmaceuticals Holdings after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Xynomic Pharmaceuticals Holdings's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2016201720182019
000-25
0000
0000
0006
00-18
0000
0000
000-10
0000
0-61063
0-61063
0000
0000
000-59
0620-57
06202
0000
000-4
0000
0000

Xynomic Pharmaceuticals Holdings stock margins

The Xynomic Pharmaceuticals Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Xynomic Pharmaceuticals Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Xynomic Pharmaceuticals Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Xynomic Pharmaceuticals Holdings's sales revenue. A higher gross margin percentage indicates that the Xynomic Pharmaceuticals Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Xynomic Pharmaceuticals Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Xynomic Pharmaceuticals Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Xynomic Pharmaceuticals Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Xynomic Pharmaceuticals Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Xynomic Pharmaceuticals Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Xynomic Pharmaceuticals Holdings Margin History

Xynomic Pharmaceuticals Holdings Gross marginXynomic Pharmaceuticals Holdings Profit marginXynomic Pharmaceuticals Holdings EBIT marginXynomic Pharmaceuticals Holdings Profit margin
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %

Xynomic Pharmaceuticals Holdings Stock Sales Revenue, EBIT, Earnings per Share

The Xynomic Pharmaceuticals Holdings earnings per share therefore indicates how much revenue Xynomic Pharmaceuticals Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Xynomic Pharmaceuticals Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Xynomic Pharmaceuticals Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Xynomic Pharmaceuticals Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Xynomic Pharmaceuticals Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Xynomic Pharmaceuticals Holdings Revenue, EBIT and net profit per share

DateXynomic Pharmaceuticals Holdings Sales per ShareXynomic Pharmaceuticals Holdings EBIT per shareXynomic Pharmaceuticals Holdings Earnings per Share
20190 undefined-0.78 undefined-0.78 undefined
20180 undefined-0.34 undefined0.11 undefined
20170 undefined-0.2 undefined-0.02 undefined
20160 undefined-0 undefined-0 undefined

Xynomic Pharmaceuticals Holdings business model

Xynomic Pharmaceuticals Holdings Inc is a biopharmaceutical company based in New York City that focuses on the development and marketing of innovative cancer therapies. The company was founded in 2016 and has since become a leading player in the industry. In this post, we would like to tell you more about the history and business model of Xynomic Pharmaceuticals, as well as the various products that the company offers. History of Xynomic Pharmaceuticals Holdings Inc Xynomic Pharmaceuticals was founded in 2016 by an experienced team of pharmaceutical industry experts, including Dr. Peng Wang, the CEO of the company. The company's goal from the beginning was to develop and bring to market innovative cancer drugs to help patients around the world. The company has made significant progress since its inception and now has an impressive portfolio of cancer therapies. Business model of Xynomic Pharmaceuticals The business model of Xynomic Pharmaceuticals is focused on developing high-quality cancer therapies and bringing them to market. The company works closely with leading academic institutions and commercial partners to identify and explore innovative concepts for combating cancer. Xynomic Pharmaceuticals' products are designed to treat specific types of cancer and be tailored to the needs of patients worldwide. Products of Xynomic Pharmaceuticals Xynomic Pharmaceuticals' portfolio includes a variety of innovative cancer therapies tailored to different types of cancer. One example is the drug Abexinostat, which is currently in phase 3 clinical trials and is used to treat peripheral T-cell lymphoma (PTCL). Abexinostat is an oral medication that targets epigenetic enzymes involved in the development of cancer. The drug has the potential to extend the survival of patients with PTCL and is a promising new treatment option for this serious disease. Another product of Xynomic Pharmaceuticals is the drug XP-102, which is used to treat fatty liver diseases. Fatty liver disease, also known as non-alcoholic fatty liver disease (NAFLD), is a common condition that occurs due to factors such as obesity and diabetes. XP-102 has the potential to improve liver performance and treat this disease, which currently has no effective medical treatment. Conclusion Xynomic Pharmaceuticals Holdings Inc is a rising biopharmaceutical company that develops innovative cancer drugs. The company has made significant progress since its inception and has an impressive portfolio of cancer therapies. Xynomic Pharmaceuticals works closely with leading partners and academic institutions to develop and provide innovative cancer therapies. The company's products have the potential to change the lives of patients worldwide and offer new treatment options for serious diseases. Xynomic Pharmaceuticals Holdings is one of the most popular companies on Eulerpool.com.

Xynomic Pharmaceuticals Holdings SWOT Analysis

Strengths

Xynomic Pharmaceuticals Holdings Inc has several strengths that contribute to its success in the pharmaceutical industry:

  • Strong pipeline of innovative drugs: Xynomic Pharmaceuticals has a robust pipeline of potential drugs that are in various stages of development. This provides the company with a diverse range of opportunities for future growth.
  • Experienced research and development team: The company employs a talented team of scientists and researchers who have expertise in drug discovery and development. This enables Xynomic Pharmaceuticals to efficiently bring new drugs to market.
  • Partnerships and collaborations: Xynomic Pharmaceuticals has established strategic partnerships and collaborations with other industry players, which allows for resource sharing, knowledge exchange, and expanded market reach.
  • Strong financial position: The company has a solid financial foundation, with sufficient funds to support its research and development efforts and pursue growth opportunities.

Weaknesses

Despite its strengths, Xynomic Pharmaceuticals Holdings Inc also faces certain weaknesses that could impede its progress:

  • Dependence on drug development success: Xynomic Pharmaceuticals heavily relies on the success of its drug development programs. If any of its key drugs fail in clinical trials or face significant regulatory challenges, it could impact the company's financial performance.
  • Limited market presence: Compared to some of its competitors, Xynomic Pharmaceuticals has a relatively smaller market presence. This could make it challenging for the company to compete effectively and gain market share.
  • Dependency on partnerships: While partnerships and collaborations can be advantageous, Xynomic Pharmaceuticals' reliance on these partnerships means that any issues or disagreements with its partners could have negative consequences for the company.

Opportunities

Xynomic Pharmaceuticals Holdings Inc has several opportunities to seize in order to grow and improve its market position:

  • Increasing demand for innovative drugs: The pharmaceutical industry is constantly evolving, and there is a growing demand for innovative drugs. Xynomic Pharmaceuticals can capitalize on this trend by successfully developing and commercializing its pipeline drugs.
  • Expanding market presence: The company can explore opportunities to expand its market presence by entering into new geographic regions or targeting underserved disease areas.
  • Strategic partnerships: Xynomic Pharmaceuticals can continue to form strategic partnerships and collaborations to gain access to additional resources, expertise, and potential market opportunities.

Threats

Xynomic Pharmaceuticals Holdings Inc should also be aware of potential threats that may impact its business in the future:

  • Intense competition: The pharmaceutical industry is highly competitive, with many established players and new entrants. Xynomic Pharmaceuticals must stay ahead of the competition by consistently delivering innovative drugs and effectively marketing them.
  • Regulatory challenges: The drug development and approval process is subject to strict regulations and oversight. Xynomic Pharmaceuticals should be prepared for potential regulatory hurdles that could delay or prevent the commercialization of its drugs.
  • Intellectual property protection: Protecting intellectual property is crucial in the pharmaceutical industry. Xynomic Pharmaceuticals must be vigilant in safeguarding its patents and other intellectual property rights from infringement or challenges.

Xynomic Pharmaceuticals Holdings Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Xynomic Pharmaceuticals Holdings historical P/E ratio, EBIT multiple, and P/S ratio

Xynomic Pharmaceuticals Holdings shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Xynomic Pharmaceuticals Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Xynomic Pharmaceuticals Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Xynomic Pharmaceuticals Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Xynomic Pharmaceuticals Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Xynomic Pharmaceuticals Holdings.

Most common questions regarding Xynomic Pharmaceuticals Holdings

What values and corporate philosophy does Xynomic Pharmaceuticals Holdings represent?

Xynomic Pharmaceuticals Holdings Inc represents a strong commitment to innovation and excellence in the pharmaceutical industry. The company's corporate philosophy focuses on developing and commercializing breakthrough oncology treatments to improve patients' lives. With a vision to become a global leader in precision medicine, Xynomic Pharmaceuticals prioritizes research and collaboration to unlock the full potential of targeted therapies. The company's core values include integrity, patient-centricity, and scientific rigor. By combining cutting-edge science with a dedication to clinical advancement, Xynomic Pharmaceuticals strives to make a meaningful impact in the field of oncology and bring hope to patients worldwide.

In which countries and regions is Xynomic Pharmaceuticals Holdings primarily present?

Xynomic Pharmaceuticals Holdings Inc is primarily present in the United States and China.

What significant milestones has the company Xynomic Pharmaceuticals Holdings achieved?

Xynomic Pharmaceuticals Holdings Inc has achieved significant milestones in its operations. The company successfully completed the Phase 1/2 clinical trials for its lead product candidate, abexinostat, a histone deacetylase inhibitor (HDACi). It has also obtained Fast Track designation from the U.S. FDA for abexinostat in combination with rituximab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Xynomic has received Orphan Drug Designation from the FDA for its other clinical-stage product, XP-102 (bucillamine), for the treatment of patients with non-alcoholic steatohepatitis. The company's achievements highlight its dedication to advancing innovative therapies for better patient outcomes.

What is the history and background of the company Xynomic Pharmaceuticals Holdings?

Xynomic Pharmaceuticals Holdings Inc has a rich history and background in the pharmaceutical industry. Established in [insert year], the company has dedicated itself to the development of innovative therapies for various diseases. Xynomic Pharmaceuticals focuses on targeting unmet medical needs, prioritizing patient well-being and improved outcomes. With a strong emphasis on research and development, the company has actively pursued collaborations and partnerships to advance its pipeline of potential drugs. As a leader in the industry, Xynomic Pharmaceuticals continues to strive towards delivering breakthrough treatments that positively impact patients' lives.

Who are the main competitors of Xynomic Pharmaceuticals Holdings in the market?

The main competitors of Xynomic Pharmaceuticals Holdings Inc in the market include established pharmaceutical companies such as Pfizer, Novartis, Roche, and Johnson & Johnson. These multinational companies have a strong presence in the pharmaceutical industry and offer a wide range of therapeutic products and services. Xynomic Pharmaceuticals Holdings Inc competes with these companies by focusing on its innovative drug development pipeline and unique market positioning.

In which industries is Xynomic Pharmaceuticals Holdings primarily active?

Xynomic Pharmaceuticals Holdings Inc is primarily active in the biopharmaceutical industry.

What is the business model of Xynomic Pharmaceuticals Holdings?

The business model of Xynomic Pharmaceuticals Holdings Inc is focused on developing innovative cancer treatments. The company aims to identify and license promising drug candidates, and then advance them through clinical trials and regulatory approval processes. Xynomic Pharmaceuticals uses a strategic approach that combines in-house development with collaborations and partnerships to maximize resources and expertise. By targeting unmet medical needs and leveraging its expertise in oncology, Xynomic Pharmaceuticals aims to bring new and effective treatments to patients worldwide.

What is the P/E ratio of Xynomic Pharmaceuticals Holdings 2024?

The P/E ratio cannot be calculated for Xynomic Pharmaceuticals Holdings at the moment.

What is the P/S ratio of Xynomic Pharmaceuticals Holdings 2024?

The P/S cannot be calculated for Xynomic Pharmaceuticals Holdings currently.

What is the AlleAktien quality score of Xynomic Pharmaceuticals Holdings?

The AlleAktien quality score for Xynomic Pharmaceuticals Holdings is 4/10.

What is the revenue of Xynomic Pharmaceuticals Holdings 2024?

The revenue cannot currently be calculated for Xynomic Pharmaceuticals Holdings.

How high is the profit of Xynomic Pharmaceuticals Holdings 2024?

The profit cannot currently be calculated for Xynomic Pharmaceuticals Holdings.

What is the business model of Xynomic Pharmaceuticals Holdings

Xynomic Pharmaceuticals Holdings Inc is a rising biotech company focused on developing novel therapies for treating various types of cancer. Its business model includes research and development, clinical trials, manufacturing, and distribution of drugs. The company's research and development department is the core of the organization, where experts work on identifying and developing new compounds to combat cancer cells. Clinical trials are conducted to investigate the efficacy and safety of promising drug candidates in humans. Manufacturing involves producing the drug once clinical trials are successfully completed, often in collaboration with external partners. Xynomic Pharmaceuticals currently does not have any drugs on the market but plans to seek FDA approval in the near future. The company has several promising drug candidates, including Abexinostat, XP-105, and XP-102, which have shown positive results in clinical trials. Overall, Xynomic Pharmaceuticals is an emerging biotech company dedicated to developing innovative cancer medications.

What is the Xynomic Pharmaceuticals Holdings dividend?

Xynomic Pharmaceuticals Holdings pays a dividend of 0 USD distributed over payouts per year.

How often does Xynomic Pharmaceuticals Holdings pay dividends?

The dividend cannot currently be calculated for Xynomic Pharmaceuticals Holdings or the company does not pay out a dividend.

What is the Xynomic Pharmaceuticals Holdings ISIN?

The ISIN of Xynomic Pharmaceuticals Holdings is US98421X1028.

What is the Xynomic Pharmaceuticals Holdings ticker?

The ticker of Xynomic Pharmaceuticals Holdings is XYNO.

How much dividend does Xynomic Pharmaceuticals Holdings pay?

Over the past 12 months, Xynomic Pharmaceuticals Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Xynomic Pharmaceuticals Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Xynomic Pharmaceuticals Holdings?

The current dividend yield of Xynomic Pharmaceuticals Holdings is .

When does Xynomic Pharmaceuticals Holdings pay dividends?

Xynomic Pharmaceuticals Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Xynomic Pharmaceuticals Holdings?

Xynomic Pharmaceuticals Holdings paid dividends every year for the past 0 years.

What is the dividend of Xynomic Pharmaceuticals Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Xynomic Pharmaceuticals Holdings located?

Xynomic Pharmaceuticals Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Xynomic Pharmaceuticals Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Xynomic Pharmaceuticals Holdings from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Xynomic Pharmaceuticals Holdings pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Xynomic Pharmaceuticals Holdings in the year 2023?

In the year 2023, Xynomic Pharmaceuticals Holdings distributed 0 USD as dividends.

In which currency does Xynomic Pharmaceuticals Holdings pay out the dividend?

The dividends of Xynomic Pharmaceuticals Holdings are distributed in USD.

All fundamentals about Xynomic Pharmaceuticals Holdings

Our stock analysis for Xynomic Pharmaceuticals Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Xynomic Pharmaceuticals Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.